Plus Therapeutics, Inc. is a United States healthcare company that focuses on the development and commercialization of precision diagnostics and targeted radiopharmaceuticals for cancers of the central nervous system. The company operates a wholly owned subsidiary called CNSide Diagnostics LLC which creates and markets laboratory developed tests such as the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to detect tumor cells that have spread to the meninges. Its lead…
Plus Therapeutics, Inc. is a United States healthcare company that focuses on the development and commercialization of precision diagnostics and targeted radiopharmaceuticals for cancers of the central nervous system. The company operates a wholly owned subsidiary called CNSide Diagnostics LLC which creates and markets laboratory developed tests such as the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to detect tumor cells that have spread to the meninges. Its lead radiopharmaceutical candidate is rhenium (186 Re) obisbemeda a nanoliposome encapsulated radionuclide designed for direct delivery into brain tumors via convection enhanced catheters or intraventricular reservoirs. Another pipeline asset is Rhenium 188 NanoLiposome Biodegradable Alginate Microsphere (188 RNL BAM) intended for intra arterial treatment of liver cancers. The company’s headquarters is located in Houston Texas near major cancer research institutions.
Plus Therapeutics, Inc. generates revenue primarily through the sale of its diagnostic laboratory tests and through potential future sales of its radiopharmaceutical products. The company has secured national agreements with UnitedHealthcare Insurance Company and Humana Inc. to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to more than sixty seven million covered lives across the United States. These agreements create a reimbursement stream based on each test performed. In addition, the company receives milestone payments and grant funding from government entities such as the Cancer Prevention and Research Institute of Texas and the National Institutes of Health which support clinical development of its drug candidates. Licensing arrangements with partners such as K2bio and the University of Texas Health Science Center at San Antonio may also produce royalty payments upon commercialization. While the radiopharmaceutical candidates are still investigational, the company anticipates revenue from product sales, partnerships, and co development agreements once they receive regulatory approval.
Plus Therapeutics, Inc. occupies a niche within the oncology sector by combining precision diagnostics with targeted radiopharmaceutical approaches for central nervous system malignancies. The company competes with large pharmaceutical firms such as AstraZeneca Novartis and Bristol Myers Squibb as well as specialized biotechnology companies like Telix IQVIA and Cassiopea that are developing similar radiolabeled agents for glioma and leptomeningeal disease. In the diagnostics arena it faces competition from established laboratory test providers including LabCorp Quest Diagnostics and Neogenomics. The company’s competitive advantages stem from its proprietary nanoliposome encapsulation platform which enables high local radiation doses while sparing healthy tissue, its orphan drug and fast track designations for rhenium (186 Re) obisbemeda in recurrent GBM and leptomeningeal metastases, its CLIA certified laboratory in Houston, and its national payer agreements with UnitedHealthcare and Humana that provide immediate market access for its CNSide Test. Additionally the company’s pipeline includes a distinct liver cancer agent 188 RNL BAM that uses a biodegradable alginate microsphere technology offering a dual mechanism of embolization and radiation delivery.
Plus Therapeutics, Inc. serves hospitals cancer treatment centers and physicians who treat patients with central nervous system cancers and liver malignancies. The company’s diagnostic customers include UnitedHealthcare Insurance Company and Humana Inc. which provide reimbursement for the CNSide Test to their enrolled members. Additionally the company works with clinical laboratories and academic medical centers that utilize its CNSide Cerebrospinal Fluid Tumor Cell Enumeration test for research and patient care. Its future radiopharmaceutical customers are expected to be oncology departments within hospitals and specialized infusion centers capable of administering convection enhanced or intraventricular deliveries. The company also collaborates with government agencies such as the Cancer Prevention and Research Institute of Texas the National Institutes of Health and the Department of Defense which provide grant funding and support clinical trials.